Results presented below are derived from data collected from over 475 news feeds.
Click on one of these terms to refine your search
5 stories
(Reuters Health) - With improved effectiveness of hepatitis C treatments, it's worthwhile to screen U.S. adults for the virus, an expert panel says.
Shares of Spring Bank Pharmaceuticals plummeted 26% on Wednesday after the company said it would end the development of an experimental drug to treat chronic hepatitis B virus, following the death of a patient in a mid-stage trial.
Spring Bank Pharmaceuticals said on Wednesday it has discontinued the development of its experimental drug to treat chronic hepatitis B virus (HBV), following the death of a patient in a mid-stage trial.
A mutation switches the turbo on during virus replication.
The US Preventive Services Task Force now recommends screening for hepatitis C infection in all adults ages 18 to 79 without known liver disease, regardless of their risk.